Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day

Journal of the American Academy of Dermatology

Volumn 38, Issue 5 III, 1998, Pages

  De Backer, M ^a   De Vroey, C ^a   Lesaffre, E ^a   Scheys, I ^a   De Keyser, P ^a  

^a Novartis Medical Department   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FUNGUS CULTURE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TASTE DISORDER; VERTIGO;

EID: 0031946068     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(98)70486-4     Document Type: Article

References (25)

1. DT Roberts Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey Br J Dermatol 126 suppl 39 1992 23 27
2. HC Korting M. Schafer-Korting Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin Arch Dermatol 128 1992 243 248
3. G Petranyi JG Meingassner H. Mieth Antifungal activity of the allylamine derivative terbinafine in vitro Antimicrob Agents Chemother 31 1987 1365 1368
4. JA Balfour D. Faulds Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses Drugs 43 1992 259 284
5. I Schuster NS Ryder Allylamines –mode and selectivity of action compared to azole antifungals, and biological gate in mammalian organisms J Dermatol Treat 1 suppl 2 1990 7 9
6. M Willemsen P De Doncker J Willems Posttreatment itraconazole levels in the nail J Am Acad Dermatol 26 1992 731 735
7. D Roseeuw P. De Doncker New approaches to the treatment of onychomycosis J Am Acad Dermatol 29 1993 45 50
8. AY Finlay Pharmacokinetics of terbinafine in the nail Br J Dermatol 126 suppl 39 1992 28 32
9. JL. Hintze BMDP Statistical Software 1991 1991 Los Angeles, CA 90025
10. SAS Institute Inc 4th ed SAS/STAT User's Guide, Version 6 Vol 1 1989 SAS Institute Inc Cary (NC)
11. M Bräutigam S Nolting RE Schopf G. Weidinger Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection Br Med J 311 1995 919 922
12. R Arenas J Dominguez-Cherit LMA Fernandez Open randomized comparison of itraconazole versus terbinafine in onychomycoses Int J Dermatol 34 1995 138 143
13. H Hofmann M Bräutigam G Weidinger H. Zaun Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin Arch Dermatol 131 1995 919 922
14. J Faergemann C Anderson K Hersle Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis J Am Acad Dermatol 32 1995 750 753
15. M De Backer P De Keyser DL Massart KJ Westelinck Terbinafine (Lamisil) 250 mg/day and 500 mg/day are equally effective in a 16 week oral treatment of toenail onychomycosis: a double-blind multicentre trial RJ Hay International perspective on Lamisil. 1994 CCT Healthcare Communications London, UK 39 43
16. MJD Goodfield Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial Br J Dermatol 126 suppl 39 1992 33 35
17. JG Van Der Schroeff PKS Cirkel MB Crijns TJ Van Dijk FJ Govaert DA Groeneweg A randomized treatment duration-finding study of terbinafine in onychomycosis Br J Dermatol 126 suppl 39 1992 36 39
18. L'itraconazole pour le traitement de l'onychomycose Med Lett Drugs Ther (édition française) 18 1996 15 16
19. RB Odom CR Daniel Itraconazole 200 mg daily for the treatment of toenail onychomycosis: a double-blind, placebo-controlled study Poster presentation American Academy of Dermatology, New Orleans, LA, February 4–9 1995
20. Sporanox (itraconazole): US package insert (product leaflet). Janssen Pharmaceutica Inc.;1995.
21. C. De Cuyper Long term evaluation of terbinafine (Lamisil) 250 mg/day and 500 mg/day in a 16 week oral treatment of toenail onychomycosis. Poster presentation International Summit on Cutaneous Antifungal Therapy November 10-13, 1994 Boston, MA
22. SR Arikian TR Einarson G Kobelt-Nguyen F. Schubert A multinational pharmacoeconomic analysis of oral therapies for onychomycosis Br J Dermatol 130 suppl 43 1994 35 44
23. T Einarson S Arikian N. Shear Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective Br J Dermatol 130 suppl 43 1994 32 34
24. W Bergman F. Rutten Oral treatment of onychomycosis of the toenails: comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine Ned Tijdschr Geneesk 138 1994 2346 2350
25. R Davis JA Balfour Terbinafine: pharmacoeconomic evaluation of its use in superficial fungal infections Pharmacoeconomics 8 1995 253 269